The prognostic value of neurofilament light chain in serum

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Standard

The prognostic value of neurofilament light chain in serum. / Sellebjerg, Finn; Magyari, Melinda.

I: The Lancet Neurology, Bind 21, Nr. 3, 2022, s. 207-208.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Harvard

Sellebjerg, F & Magyari, M 2022, 'The prognostic value of neurofilament light chain in serum', The Lancet Neurology, bind 21, nr. 3, s. 207-208. https://doi.org/10.1016/S1474-4422(22)00034-5

APA

Sellebjerg, F., & Magyari, M. (2022). The prognostic value of neurofilament light chain in serum. The Lancet Neurology, 21(3), 207-208. https://doi.org/10.1016/S1474-4422(22)00034-5

Vancouver

Sellebjerg F, Magyari M. The prognostic value of neurofilament light chain in serum. The Lancet Neurology. 2022;21(3):207-208. https://doi.org/10.1016/S1474-4422(22)00034-5

Author

Sellebjerg, Finn ; Magyari, Melinda. / The prognostic value of neurofilament light chain in serum. I: The Lancet Neurology. 2022 ; Bind 21, Nr. 3. s. 207-208.

Bibtex

@article{89a48f9eecc94aa289820848c91997e6,
title = "The prognostic value of neurofilament light chain in serum",
author = "Finn Sellebjerg and Melinda Magyari",
note = "Funding Information: FS declares grants from Biogen, Merck, Novartis, Roche, and Sanofi Genzyme; consulting fees from Novartis; speaking fees from Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, and Sanofi Genzyme; travel support from Biogen and Roche; and fees for participating on a Data Safety Monitoring Board from Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, and Sanofi Genzyme. MM declares grants from Biogen Idec, Merck, Danish Multiple Sclerosis Society, Roche, Novartis, and Sanofi; speaking fees from Novartis, Bristol Myers Squibb, Roche, Biogen, and Merck; and travel support from Sanofi.",
year = "2022",
doi = "10.1016/S1474-4422(22)00034-5",
language = "English",
volume = "21",
pages = "207--208",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "TheLancet Publishing Group",
number = "3",

}

RIS

TY - JOUR

T1 - The prognostic value of neurofilament light chain in serum

AU - Sellebjerg, Finn

AU - Magyari, Melinda

N1 - Funding Information: FS declares grants from Biogen, Merck, Novartis, Roche, and Sanofi Genzyme; consulting fees from Novartis; speaking fees from Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, and Sanofi Genzyme; travel support from Biogen and Roche; and fees for participating on a Data Safety Monitoring Board from Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, and Sanofi Genzyme. MM declares grants from Biogen Idec, Merck, Danish Multiple Sclerosis Society, Roche, Novartis, and Sanofi; speaking fees from Novartis, Bristol Myers Squibb, Roche, Biogen, and Merck; and travel support from Sanofi.

PY - 2022

Y1 - 2022

U2 - 10.1016/S1474-4422(22)00034-5

DO - 10.1016/S1474-4422(22)00034-5

M3 - Comment/debate

C2 - 35182499

AN - SCOPUS:85124630567

VL - 21

SP - 207

EP - 208

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 3

ER -

ID: 299216528